Author Index
Volumes 33 and 34

A
Abebe W, 34:157
Absenger A, 34:211
Adams SP, 34:109
Akkermans LM, 33:129
Alexander B, 34:203
Ali S, 34:157
Appleyard CB, 33:231
Arroyo CM, 33:109
Aslam M, 34:203
Atassi G, 33:35

B
Baer H-P, 33:197
Bain AI, 34:109
Baker GB, 34:117, 34:143
Bath C, 33:153
Baxi MD, 33:121
Beck PL, 33:231
Benjamin IS, 34:203
Berger ML, 34:79
Blann E, 33:213
Bomzon A, 33:205
Boschi G, 33:29
Braodley KJ, 34:187
Brennand J, 33:153
Brown D, 33:171
Buckner CK, 33:47

C
Carballo DD Jr, 33:113
Carstens DD, 34:57
Carter L, 33:231
Cascieri MA, 33:179
Cervoni P, 34:1
Chaney W, 33:1
Conklin R, 33:47
Conner MW, 33:53
Connolly TM, 33:53
Cordes CT, 33:231
Corradi C, 34:63
Corsi M, 34:37
Coughtrie MWH, 34:89
Coutts RT, 34:117, 34:143
Crapo JD, 34:57
Croiset G, 33:129

D
Dai S, 33:101
Davies A, 33:153
Day BJ, 34:57
Dupin S, 33:11

E
Ediss C, 34:165
Eickhoff CV, 33:23
End DW, 34:219
Endres S, 34:29
Ergun E, 34:17

F
Falk PM, 33:113
Ferslew KE, 34:169
Finch AM, 34:133
Fishleder RI, 33:47
Florin TH, 34:133
Folkerts PAJ, 34:103
Fong TM, 33:179
Forbes KJ, 34:89
Ford J, 34:9
Forloni G, 33:221
Fujita T, 33:53

G
Galmiche JP, 34:63
Gandolphi MA, 34:63
Garrabrant TA, 34:219
Genissel P, 33:11
Giles AR, 34:175
Goodnough DB, 34:143
Grant C, 33:17
Grant GJ, 34:23
Graziano FM, 33:47
Grove KL, 33:83

H
Haen E, 34:29
Harper GP, 34:97
Hashjin GS, 34:103
Hatch A, 34:57
Hegadoren KM, 34:117
Heiny O, 33:147
Henricks PAJ, 34:103
Heron AE, 34:133
Hofer D, 34:211
Horn EH, 34:175
Houin G, 33:11
Houston JB, 34:9
Hu W, 34:1
Hume R, 34:89

I
Ivy D, 33:213

J
Janny SJ, 33:109
Jeremic G, 33:221
Jones RE, 33:171
Joshi S, 33:1

K
Kanekal S, 33:171
Karran EH, 34:97
Kato M, 33:91
Kenakin TP, 34:37
Kiss R, 33:35
Krishnamoorthy C, 34:37
Kroese ABA, 33:129
Krummel DAP, 33:75

Journal of Pharmacological and Toxicological Methods 34, 231–232 (1995)

© 1995 Elsevier Science Inc.

655 Avenue of the Americas, New York, NY 10010

1056-8719/95/$9.50
SSDI 1056-8719(95)00123-9

JPM Vol. 34, No. 4
December 1995;231–232

L
Langerman L, 34:23
Lapin IP, 34:73
Latini R, 33:221
Launay N, 33:29
Law FCP, 33:23
Le Quellec A, 33:11
Le T, 33:231
Levy BI, 33:159
Lewis CA, 34:187
Liebmann PM, 34:211
Liu H, 34:175
Losert U, 34:17
Lu X-Y, 33:83
Ludbrook G, 33:17
Lutz M, 34:37
Luvarà G, 33:221
Lyle EM, 33:53
Lynch JL Jr, 33:53

M
Makujina SR, 34:157
Malek A, 33:213
Mapleson WW, 34:199
Marchand B, 33:11
Martin SW, 34:9
Masseroli M, 33:221
Mattison DR, 33:213
Maurice DH, 34:175
McNeill JH, 33:101
Melchert RB, 33:187
Mendenhall WA, 34:225
Menius JA, 34:37
Messori A, 33:221
Mitchelson F, 34:215
Miyamoto M, 33:91
Mody R, 33:1
Moeller J, 34:29
Moore TJ, 33:75
Morgan PH, 34:37
Mudumbi RV, 34:225
Müller MR, 34:17
Murray AGW, 34:215
Mustafa SJ, 34:157

N
Nijkamp FP, 34:103

O
Oberle RL, 33:75
Olivetti G, 33:221
Olson RD, 34:225
Orcutt RH, 34:169

P
Pancheva SN, 33:137
Pauwels O, 33:35
Peereboom-Stegman JHJC, 34:47
Penhall C, 33:17
Pierce TL, 34:149
Piskoun B, 34:23
Pöch G, 33:137, 33:197
Porta S, 34:211
Porzio S, 33:221
Pulaki S, 34:17

Q
Qiu HY, 33:159

R
Raper C, 34:149
Raptopoulos D, 34:199
Reiffenstein RJ, 33:197
Rimele T, 34:37
Rips R, 33:29
Riva E, 33:221
Robertson JW, 33:187
Russell FGM, 34:47

S
Sabater RT, 33:113
Sahai A, 33:171
Said O, 33:205
Saivin S, 33:11
Salat A, 34:17
Sanderson SD, 34:133
Sarich TC, 34:109
Scarpignato C, 34:63
Schauenstein K, 34:211
Scherrmann J-M, 33:29
Schreiner W, 34:17
Semmler J, 34:29
Senis YA, 34:175
Sharp S, 34:89
Shen A, 34:215
Sinha B, 34:29
Smith PA, 33:63
Smithgall TE, 34:125
Sokol PT, 34:1
Speth RC, 33:83
Staddon GE, 34:199
Stam R, 33:129
Stangl P, 34:17
Strader CD, 33:179
Stuyker-Boudier HAJ, 33:159
Sugawara T, 33:91

T
Takayama S, 33:91
Tam YK, 34:165
Tang E, 33:153
Taylor SM, 34:133
Thurmond TS, 34:169
Thut PD, 33:231
Tolhurst SL, 34:133
Toral J, 34:1
Turner MD, 33:231

U
Uhlig S, 33:147
Upton R, 33:17

V
Valtier B, 33:159
van der Aa EM, 34:47
Vestal RE, 34:225
Vishwanatha JK, 33:121
Vlasuk GP, 33:53

W
Wall RA, 34:109
Wallace JL, 33:231
Weaver BMQ, 34:199
Weiss U, 34:211
Welder AA, 33:187
Whiting E, 33:153
Wiegant VM, 33:129
Wolner E, 34:17
Wright JM, 34:109
Wynn RL, 33:231

Z
Zakowski MI, 34:23
Zhang KL, 33:83
Zhou T, 34:109
Ziai R, 34:1
Zimmermann P, 34:211

ELSEVIER

Subject Index
Volumes 33 and 34

A

Acetylcholine, extraction for HPLC analysis, 34:215
Additive dose-response curves, 33:137
Aggregometry, whole blood, 34:17
Airway hyperreactivity, in vitro, spasmogen inhalations and, 34:187
Airway responsiveness, bovine trachea and, 34:103
ALL-FIT, additive dose-response curves, 33:137
Amphetamine, methylenedioxy analogs, 34:117
Anabolic-androgenic steroids, toxic effects, 33:187
Analgesia, measurement, 33:17
Anesthesia, measurement, 33:17
Angioplastic injury, factor X_a, platelet adhesion, heparin, and aspirin effects, 33:53
Angiotensin II receptor binding, tissue freezing effects, 33:83
Animal model, hapten-induced chronic colitis, 33:237
Antacids, gastric mucosal damage and, 34:63
Antagonism, dose-response curves and, 33:197
Anti-cancer alkylating drugs, effects, 33:35
Anti-cancer drug design, SH2 and SH3 domains and, 34:125
Anti-peptide antibodies, sulphotransferases and, 34:89
Antidepressants, simultaneous assay of fluoxetine, norfluoxetine, and desipramine, 34:143
Antigens, guinea-pig trachea and, 33:47
Antivesicant, topical skin protectants, 33:109
Ap_4A, biological functions and physiological significance, 33:121
Area under drug plasma concentration (AUC), computer program, 34:165
Argininosuccinic acid lyase, hepatotoxicity and, 34:109
Arterial thrombosis, angioplastic injury and, 33:53
Aseptic operation, small bowel motility, 33:129
Aspirin
  angioplastic injury and, 33:53
  gastric mucosal damage and, 34:63
AT_1, tissue freezing effects, 33:83
AT_2, tissue freezing effects, 33:83
Atenolol, cardiac contractility and, 34:225
Atherosclerosis, factor X_a, platelet adhesion, heparin, and aspirin effects, 33:53

B

Benzoylecgonine, cocaine and, 33:113
β- and γ-Emitters, imaging and quantitation, 33:171
β_1-blocker, cardiac contractility and, 34:225
Bile duct manipulation, peripheral vascular neuroeffector mechanisms and, 33:205
Blood-sampling, freely moving rats and chronic, 34:211
Blood vessel, cAMP phosphodiesterase expression, 34:175
Bovine trachea, airway responsiveness and, 34:103
Brain microdialysis, 33:29
Bronchoalveolar lavage, cytologic analyses and, 34:57
Buffer component, cyclic AMP radioimmunoassays cross-reactivity with, 34:29

C

^{14}C isotopes, imaging and quantitation, 33:171
C5a, effects on placenta, 34:133
cAMP phosphodiesterase, cell layer-specific expression, 34:175
Cancer, lectins and, 33:1
Cannulation, freely moving rats and long-term, 34:211
Cardiac contractility, punctate and field electrical stimulation and, 34:225
Cell culture, cyclic AMP radioimmunoassays cross-reactivity and, 34:29
Cell cycle effects, anticancer alkylating drugs, 33:35
Cell isolation, for cytologic analyses, 34:57
Chemotaxis, neutrophils and, 33:91
Chirality, methylenedioxy analogs of amphetamine, 34:117
CHO cells, $^{86}Rb^+$ efflux through potassium channels, 34:1
Choline, extraction for HPLC analysis, 34:215
Chronic blood-sampling, freely moving rats and, 34:211
Cloning, molecular, 34:175
Clotrimazole, retinoic acid metabolism measurement and, 34:219
Cocaine
  Hep-G2 in metabolism and toxicology, 33:113

Journal of Pharmacological and Toxicological Methods 34, 233–237 (1995)

© 1995 Elsevier Science Inc.

655 Avenue of the Americas, New York, NY 10010

1056-8719/95/$9.50
SSDI 1056-8719(95)00124-7

JPM Vol. 34, No. 4
December 1995;233–237

placental function and, 33:213
Collagen degradation, proteinase inhibitors and in vivo, 34:97
Compliance, hypertension and mesenteric artery, 33:159
Computer analysis
additive dose-response curves, 33:137
small bowel motility, 33:129
Computer-controlled flushing, long-term cannulation in
freely moving rats and, 34:211
Computer program, for area under drug plasma concentration (AUC), 34:165
Confidence intervals, Schild regression and, 34:37
Contraction
hypertension and mesenteric artery, 33:159
measurement in coronary artery smooth muscle, 34:157
Coronary artery, calcium and tension measurement in smooth muscle porcine, 34:157
[^{51}Cr]-EDTA, intestinal permeability by nonsteroidal anti-inflammatory drugs and, 34:9
Cross-reactivity, cyclic AMP radioimmunoassays, 34:29
Culture medium, cyclic AMP radioimmunoassays cross-reactivity and, 34:29
Curare, guinea-pig trachea and, 33:47
Cyclic AMP, radioimmunoassays cross-reactivity, 34:29
Cytochrome P-450, isoniazid-induced hepatotoxicity, 34:109

D

Damage markers, lactate dehydrogenase and mucus as, 33:75
Data analysis, for osmotic fragility, 34:169
Desipramine, gas chromatography and, 34:143
Diadenosine polyphosphate, biological functions and physiological significance, 33:121
Diagnosis, lectins and cancer, 33:1
Dialysis, microdialysis probes calibration, 33:11
Diastolic function, punctate and field electrical stimulation and, 34:225
Diffusion, microdialysis probes calibration, 33:11
Dinucleoside polyphosphate, biological functions and physiological significance, 33:121
Distensibility, hypertension and mesenteric artery, 33:159
Dorsal hippocampus, microdialysis, 33:29
Dose ratio, quantitative estimation of potentiation and antagonism by, 33:197
Dose-response curves additive, 33:137
agonists and antagonists interaction and, 33:197
Droxicam, gastric mucosal damage and, 34:63
Drug-nutrient interaction, human term placenta and, 34:47
Dungeness crabs, xenobiotics excretion, 33:23

E

Ecgonine, cocaine and, 33:113
Ecgonine methyl ester, cocaine and, 33:113
ED_{50} values, local anesthetics on tooth pulp and, 33:231
Edema, perfused lung, 33:147
Electron paramagnetic resonance (EPR)/spin-label technique, antivesicant topical skin protectants and, 33:109
Electronic data analysis, whole blood aggregometry and, 34:17
Elevated plus-maze, 34:73
Endothelin receptors, expression and pharmacological characterization, 33:153
Enhancers, lactate dehydrogenase and mucus, 33:75
Expression, endothelin receptors, 33:153

F

Factor X_a, angioplastic injury and, 33:53
Fluoxetine, gas chromatography and, 34:143
Forskolin, guinea-pig trachea and, 33:47
Freely moving rat model, small bowel motility, 33:129
Freezing, angiotensin II receptor binding and tissue, 33:83
Fructose, fructose-induced hypertension, 33:101
Fura-2, calcium and tension measurement in smooth muscle, 34:157

G

G-protein, transduction mechanisms, 33:63
G-protein coupled receptors, common binding site for small molecules and, 33:179
Gas-liquid chromatography
for antidepressant assay, 34:143
methylenedioxy analogs of amphetamine and, 34:117
Gastric mucosal damage, nonsteroidal anti-inflammatory drug-induced, 34:63
Glutathione, anabolic-androgenic steroids and, 33:187
Glycine contamination, [^{3}H]glycine binding sites at NMDA receptor complex and, 34:79
Glycoconjugates, interaction with lectin, 33:1
Gradient of concentration, microdialysis probes calibration, 33:11

H

^{3}H isotopes, imaging and quantitation, 33:171
Half-mustard gas (H-MG), antivesicant topical skin protectants and, 33:109

Handling
elevated plus-maze and, 34:73
morphine dependence and, 34:149
Hapten, inflammatory bowel disease induced by, 33:237
Hematocrit, whole blood aggregometry and, 34:17
Heparin, angioplastic injury and, 33:53
Hepatic cell lines
anabolic-androgenic steroids and, 33:187
cocaine and, 33:113
Hepatic necrosis, argininosuccinic acid lyase and, 34:109
Hepatotoxicity
anabolic-androgenic steroids, 33:187
isoniazid-induced, 34:109
[^{3}H]glycine binding sites, NMDA receptor complex and, 34:79
Histamine release, guinea-pig trachea and, 33:47
Hot plate, morphine tolerance and tail flick vs., 34:23
HPLC analysis, ion-pair extraction, 34:215
HPLC-ED, brain microdialysis and, 33:29
Hydrolytic metabolism, cocaine and, 33:113
Hyperglycemia, fructose-induced, 33:101
Hyperglyceridemia, fructose-induced, 33:101
Hyperinsulinemia, fructose-induced, 33:101
Hypertension
fructose-induced, 33:101
mesenteric artery and, 33:159

I
^{125}I-sarcosine^1, tissue freezing effects, 33:83
Image analysis, myocardial infarction, 33:221
Imaging, storage-phosphor autoradiography for radioisotope quantitation, 33:171
Immunoassay, cyclic AMP radioimmunoassays cross-reactivity, 34:29
Immunoblotting, anti-peptide antibodies and, 34:89
In vitro, airway hyperreactivity, 34:187
In vivo, collagen degradation, 34:97
Independent curves, 33:137
Indomethacin, gastric mucosal damage and, 34:63
Inflammation
hapten-induced chronic colitis, 33:237
proteinase inhibitors and, 34:97
Inflammatory bowel disease, hapten-induced, 33:237
Intestinal irritation, lactate dehydrogenase and mucus effects, 33:75
Intestine, nonsteroidal anti-inflammatory drugs and, 34:9
Intracellular perfusion, transduction mechanisms, 33:63
Ion-pair extraction, for HPLC analysis, 34:215
Isolated organ perfusion, 34:203
Isoleucine^8 angiotensin II (^{125}I-SI AII), tissue freezing effects, 33:83
Isoniazid, hepatotoxicity with, 34:109
Isoproterenol, guinea-pig trachea and, 33:47

K
Ketoconazole, retinoic acid metabolism measurement and, 34:219

L
Lactate dehydrogenase
anabolic-androgenic steroids and, 33:187
effects, 33:75
Lagrange, area under drug plasma concentration (AUC) and, 34:165
Lectins, cancer and, 33:1
Lens, image analysis of infarcted rat heart and, 33:221
Liarozole, retinoic acid metabolism measurement and, 34:219
Lidocaine, effects on tooth pulp, 33:231
Linoelaidic acid, perfused lung and, 33:147
Liver function tests, perfusion and, 34:203
Local anesthetic duration, effects on tooth pulp, 33:231
Local anesthetic potency, effects on tooth pulp, 33:231
Locus control region, endothelin receptor expression and, 33:153
Loss from stored blood, propofol, 34:199
Lung
isolated, ovalbumin-induced in vitro hyperreactivity and
spasmogen inhalations, 34:187
perfused, negative pressure ventilation and, 33:147

M
M-current, transduction mechanisms, 33:63
Mathematical modeling, for osmotic fragility, 34:169
Maze, elevated plus-, 34:73
Measurement, propofol, 34:199
Mechanism of action, anticancer alkylating drugs, 33:35
MEL cells, endothelin receptors and, 33:153
Mepivacaine, effects on tooth pulp, 33:231
Mesenteric artery, hypertension and, 33:159
Metabolic N-dealkylation, methylenedioxy analogs of amphetamine and, 34:117
Metabolites, urine collection for xenobiotics excretion and, 33:23
Metastasis, lectins and, 33:1
Methylenedioxy analogs of amphetamine, 34:117
Methylxanthine, cyclic AMP radioimmunoassays cross-reactivity and, 34:29

JPM Vol. 34, No. 4
December 1995;233–237

Mice
brain microdialysis, 33:29
elevated plus-maze, 34:73
Microdialysis
brain, 33:29
probes calibration, 33:11
Migrating motility complex, small intestine, 33:129
Miniature membrane oxygenator, isolated rat liver perfusion and, 34:203
Morphine
handling procedures and dependence, 34:149
hot plate vs. tail flick in acute tolerance, 34:23
Morphonuclear modifications, anticancer alkylating drugs, 33:35
Mucus, effects, 33:75
Multivariate analyses, anticancer alkylating drugs, 33:35
Muscarine, transduction mechanisms, 33:63
Myocardial infarction, image analysis, 33:221

N

Naloxone-precipitated withdrawal, from morphine, 34:149
Neutral red, anabolic-androgenic steroids and, 33:187
Neutrophils, species-dependent differences in chemotactic responses, 33:91
Nitrogen-phosphorus detector, gas chromatography with, 34:143
NK1 receptor, small-nolecule antagonists and, 33:179
NMDA receptor complex, [^{3}H]glycine binding sites at, 34:79
Nonsteroidal anti-inflammatory drugs
gastric mucosal damage and, 34:63
intestinal permeability and, 34:9
Noradrenergic tone, cardiac contractility and, 34:225
Norepinephrine uptake, bile duct manipulation and, 33:205
Norfluoxetine, gas chromatography and, 34:143
Nucleus accumbens, brain microdialysis, 33:29

O

Organ perfusion, isolated, 34:203
Osmotic fragility, mathematical modeling, 34:169
Ovalbumin-sensitized guinea pigs, spasmogen inhalations and, 34:187

P

Pain, sedation and analgesia measurement, 33:17
Paraformaldehyde, molecular cloning and, 34:175
Parameter estimation, for area under drug plasma concentration (AUC), 34:165
Paraquat, cytologic analyses and, 34:57
Patch clamp, transduction mechanisms, 33:63
Percoll gradients, for neutrophil separation, 33:91
Perfusion
cocaine and placental function and in vitro, 33:213
freely moving rats and long-term, 34:211
isolated rat liver, 34:203
long-term cannulation in freely moving rats, 34:211
negative pressure ventilation and lung, 33:147
pressure in placenta, 34:133
Peripheral blood, neutrophil separation, 33:91
Permeability markers, nonsteroidal anti-inflammatory drugs, 34:9
Pharmacokinetics, area under drug plasma concentration (AUC) and, 34:165
Pharmacology, sedation and analgesia measurement, 33:17
Phenobarbital, isoniazid-induced hepatotoxicity and, 34:109
Phosphatidylinositol-3′ kinase, SH2 and SH3 domains in anti-cancer drug design and, 34:125
Phosphodiesterase inhibitors, cyclic AMP radioimmunoassays
cross-reactivity with, 34:29
Placenta
C5a and U46619 effects on, 34:133
cocaine and human, 33:213
human term, 34:47
placenta membrane vesicle isolation, 34:47
Plasma-catecholamines, long-term cannulation in freely
moving rats and, 34:211
Platelet-activating factor (PAF), perfused lung and, 33:147
Platelet adhesion inhibition, angioplastic injury and, 33:53
Platelet count, whole blood aggregometry and, 34:17
Platelet deposition, angioplastic injury and, 33:53
Polymorphonuclear leukocytes, cytologic analyses and, 34:57
Porcine coronary artery, calcium and tension measurement in smooth muscle, 34:157
Potassium channels, $^{86}Rb^+$ efflux through recombinant, 34:1
Potential difference, nonsteroidal anti-inflammatory drug-induced gastric mucosal damage, 34:63
Potentiation, dose-response curves and, 33:197
Procaine, effects on tooth pulp, 33:231
Propofol, blood sample storage and, 34:199
Protein kinase, transduction mechanisms, 33:63
Proteinase inhibitors, in vivo collagen degradation and, 34:97
^{195m}Pt isotopes, imaging and quantitation, 33:171
Punctate and field electrical stimulation, cardiac contractility and, 34:225

R
Rabbit, local anesthetics on tooth pulp, 33:231
Ras, SH2 and SH3 domains in anti-cancer drug design, 34:125
Rats
  fructose-induced hypertension, 33:101
  hippocampal membranes, [^{3}H]glycine binding sites at NMDA receptor complex and, 34:79
  hot plate vs. tail flick in morphine tolerance, 34:23
  image analysis of infarcted heart, 33:221
  long-term perfusion in freely moving, 34:211
  tissue freezing effects, 33:83
$^{86}Rb^+$ efflux, through recombinant potassium channels, 34:1
Recombinant expression, $^{86}Rb^+$ efflux through potassium channels, 34:1
Recovery, microdialysis probes calibration, 33:11
Red blood cell hemolysis, osmotic fragility test for, 34:169
Relaxation
  measurement in coronary artery smooth muscle, 34:157
  punctate and field electrical stimulation and cardiac, 34:225
Resampling, Schild regression and, 34:37
Reserpine, cardiac contractility and, 34:225
Retinoic acid, metabolism measurement, 34:219

S
Saline injection, elevated plus-maze and, 34:73
Schild regression, resampling methods for, 34:37
SH2 domains, anti-cancer drug design and, 34:125
SH3 domains, anti-cancer drug design and, 34:125
Sham injection, elevated plus-maze and, 34:73
Sheep, propofol pharmacokinetics, 34:199
Site of action, additive dose-response curves, 33:137
Slope, dose-response curves, 33:197
Small bowel motility, 33:129
Small molecules, common binding site, 33:179
Smooth muscle contraction, airway responsiveness and, 34:103
Spasmogen inhalations, ovalbumin-induced in vitro hyperreactivity and, 34:187
Species variety, neutrophils, 33:91
Spin labeling, antivesicant topical skin protectants and, 33:109
Statistics, Schild regression and, 34:37
Steroids, anabolic-androgenic, toxic effects, 33:187
Storage-phosphor autoradiography, radioisotope quantitation, 33:171
Stress-free, freely moving rats and long-term cannulation, 34:211
Sucralfate, gastric mucosal damage and, 34:63
Sulphation, anti-peptide antibodies and, 34:89
Sulphotransferases, anti-peptide antibodies and, 34:89
Surfactants, lactate dehydrogenase and mucus, 33:75
Sympathetic ganglion, transduction mechanisms, 33:63
Syncytial microvillous membrane vesicles, isolation from placenta, 34:47

T
Tail flick, morphine tolerance and hot plate vs., 34:23
Temperature, propofol, 34:199
Therapy, lectins and cancer, 33:1
Tissue culture, cocaine metabolism, 33:113
Tolerance, hot plate vs. tail flick in morphine, 34:23
Topical skin protectants, antivesicant, 33:109
Toxicokinetics, urine collection for xenobiotics excretion and, 33:23
Toxicologic response, cocaine, 33:113
Trachea
  airway responsiveness and bovine, 34:103
  isoproterenol and forskolin effects, 33:47
  ovalbumin-induced in vitro hyperreactivity and spasmogen inhalations, 34:187
Transport, cocaine and placental function, 33:213
Trinitriobenzene sulfonic acid, inflammatory bowel disease induced by, 33:237
Tyrosine kinase, SH2 and SH3 domains and, 34:125

U
U46619
  effects on placenta, 34:133
  perfused lung and, 33:147
U-tube, transduction mechanisms, 33:63
Urine collection system, Dungeness crabs xenobiotics excretion, 33:23

V
Vascular reactivity, bile duct manipulation and, 33:205

W
Weight measurement
  perfused lung, 33:147
  placenta, 34:133
Whole-cell recording, transduction mechanisms, 33:63

X
Xenobiotics
  cocaine and, 33:113
  urine collection system for excretion, 33:23